Home World News Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and... World News Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 498 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? July 27, 2021 FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer October 22, 2021 Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... July 5, 2018 Improving research with registered reports May 16, 2022 Load more HOT NEWS Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... Mothers Raise Girls Together After Discovering They Were Swapped At Birth Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously... Is AI Ready to Play a Leading Role in Colorectal Cancer...
